MedPath

Mitoxantrone

Generic Name
Mitoxantrone
Drug Type
Small Molecule
Chemical Formula
C22H28N4O6
CAS Number
65271-80-9
Unique Ingredient Identifier
BZ114NVM5P
Background

An anthracenedione-derived antineoplastic agent.

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
Associated Therapies
Autologous hematopoietic stem cell transplant
Clinical Trials
Related News

Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Phase 1
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2013-09-20
Lead Sponsor
Lymphoma Trials Office
Target Recruit Count
30
Registration Number
NCT00032149
Locations
🇬🇧

King's College Hospital, London, England, United Kingdom

🇬🇧

St. Georges, University of London, London, England, United Kingdom

🇬🇧

Cheltenham General Hospital, Cheltenham, England, United Kingdom

and more 1 locations

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2016-02-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
170
Registration Number
NCT00002766
Locations
🇺🇸

Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 4 locations

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2003-01-27
Last Posted Date
2013-06-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
30
Registration Number
NCT00002598
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-12-19
Lead Sponsor
University Hospital Birmingham
Target Recruit Count
2250
Registration Number
NCT00003893
Locations
🇬🇧

Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Phase 1
Conditions
Prostate Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-12-19
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Target Recruit Count
12
Registration Number
NCT00003633
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3
Completed
Conditions
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
First Posted Date
2003-01-27
Last Posted Date
2013-12-18
Lead Sponsor
Leukemia Research Fund
Target Recruit Count
2000
Registration Number
NCT00005823
Locations
🇬🇧

University Hospital of Wales, Cardiff, Wales, United Kingdom

🇬🇧

University College Hospital, London, England, United Kingdom

🇬🇧

Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2
Completed
Conditions
Prostate Cancer
First Posted Date
2003-01-27
Last Posted Date
2023-06-22
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT00005847
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

🇺🇸

Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States

and more 16 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2003-01-27
Last Posted Date
2010-06-22
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT00002517
Locations
🇫🇷

Centre Hospitalier Regional et Universitaire d'Angers, Angers, France

🇧🇪

Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

🇧🇪

Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium

and more 20 locations

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Phase 2
Completed
Conditions
Leukemia
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
3
Registration Number
NCT00047021
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-11-06
Lead Sponsor
Royal Marsden NHS Foundation Trust
Registration Number
NCT00004237
Locations
🇬🇧

Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy